BioCryst Stockholders Approve Stock Incentive Plan Amendment

BioCryst ( (BCRX) ) has shared an announcement.

On June 11, 2025, George B. Abercrombie announced his retirement from BioCryst‘s Board of Directors, effective at the 2025 Annual Meeting. The company expressed gratitude for his 13 years of service. On June 12, 2025, BioCryst’s stockholders approved an amendment to the Stock Incentive Plan, increasing available shares by 11 million. The meeting also included the election of directors, ratification of Ernst & Young LLP as accountants, and approval of executive compensation.

The most recent analyst rating on (BCRX) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.

Spark’s Take on BCRX Stock

According to Spark, TipRanks’ AI Analyst, BCRX is a Neutral.

BioCryst’s strong technical momentum and positive earnings call drive the score higher, despite financial instability. Regulatory successes and strategic leadership changes also support the score, but persistent net losses and negative equity pose significant risks.

To see Spark’s full report on BCRX stock, click here.

More about BioCryst

BioCryst Pharmaceuticals, Inc. is a Delaware-based company operating in the pharmaceutical industry, focusing on the development and commercialization of treatments for rare diseases.

Average Trading Volume: 4,493,313

Technical Sentiment Signal: Buy

Current Market Cap: $2.17B

See more insights into BCRX stock on TipRanks’ Stock Analysis page.